Increased serum levels of high‐mobility group box 1 protein in patients who developed acute graft‐versus‐host disease after allogeneic hematopoietic stem cell transplantation
2010; Wiley; Volume: 85; Issue: 4 Linguagem: Inglês
10.1111/j.1600-0609.2010.01507.x
ISSN1600-0609
AutoresToshiaki Yujiri, Kozo Tagami, Yoshinori Tanaka, Noriyuki Mitani, Yukinori Nakamura, Koichi Ariyoshi, Toshihiko Ando, Yukio Tanizawa,
Tópico(s)Advanced Glycation End Products research
ResumoEuropean Journal of HaematologyVolume 85, Issue 4 p. 366-367 Increased serum levels of high-mobility group box 1 protein in patients who developed acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Toshiaki Yujiri, Toshiaki Yujiri Department of Haematopoietic Stem Cell and Leukemia Research Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorKozo Tagami, Kozo Tagami Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorYoshinori Tanaka, Yoshinori Tanaka Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorNoriyuki Mitani, Noriyuki Mitani Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorYukinori Nakamura, Yukinori Nakamura Department of Haematopoietic Stem Cell and Leukemia Research Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorKoichi Ariyoshi, Koichi Ariyoshi Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorToshihiko Ando, Toshihiko Ando Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorYukio Tanizawa, Yukio Tanizawa Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this author Toshiaki Yujiri, Toshiaki Yujiri Department of Haematopoietic Stem Cell and Leukemia Research Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorKozo Tagami, Kozo Tagami Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorYoshinori Tanaka, Yoshinori Tanaka Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorNoriyuki Mitani, Noriyuki Mitani Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorYukinori Nakamura, Yukinori Nakamura Department of Haematopoietic Stem Cell and Leukemia Research Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorKoichi Ariyoshi, Koichi Ariyoshi Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorToshihiko Ando, Toshihiko Ando Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this authorYukio Tanizawa, Yukio Tanizawa Third Department of Internal Medicine, Yamaguchi University School of Medicine, Ube, Yamaguchi, JapanSearch for more papers by this author First published: 26 July 2010 https://doi.org/10.1111/j.1600-0609.2010.01507.xCitations: 8 Toshiaki Yujiri, MD, PhD, Department of Haematopoietic Stem Cell and Leukemia Research, Yamaguchi University School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan.Tel: 0836 22 2251; Fax: 0836 22 2342; e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Campana L, Bosurgi L, Rovere-Querini P. HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol 2008; 20: 518–23. 2 Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 2008; 10: 209–18. 3 Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001; 29: 259–77. 4 Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81: 1–5. 5 Yang R, Harada T, Mollen KP, et al. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med 2006; 12: 105–14. 6 Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203: 1637–42. 7 Kornblit B, Masmas T, Petersen SL, Madsen HO, Heilmann C, Schejbel L, Sengeløv H, Müller K, Garred P, Vindeløv L. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16: 239–52. Citing Literature Volume85, Issue4October 2010Pages 366-367 ReferencesRelatedInformation
Referência(s)